Evidence map›Paper›PMID 29527500›Full record

ArticleNeuroImage. Clinical2018

Metabolic brain networks in aging and preclinical Alzheimer's disease.

Katelyn L Arnemann, Franziska Stöber, Sharada Narayan, Gil D Rabinovici, William J Jagust

Abstract read
In one paragraph

Article in NeuroImage. Clinical, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Metabolism-weighted brain connectome reveals synaptic integration and vulnerability to neurodegeneration.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Stable brain PET metabolic networks using a multiple sampling scheme.Network neuroscience (Cambridge, Mass.) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Brain Network Organization and Aging.Advances in experimental medicine and biology · 2023
    Article
  12. Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.European journal of nuclear medicine and molecular imaging · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Katelyn L ArnemannHelen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, United States. Electronic address: klarnemann@berkeley.edu.
Franziska StöberHelen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, United States; Leibniz Institute for Neurobiology, Magdeburg, Germany; Clinic for Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Sharada NarayanHelen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, United States.
Gil D RabinoviciHelen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, United States; Memory and Aging Center, University of California San Francisco, San Francisco, CA, United States.
William J JagustHelen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, United States; Division of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, United States.

Funding

PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Neural and Biochemical Mechanisms of Cognitive AgingR01AG034570 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI William J. Jagust · 2009 to 2026
$12.0M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG034570NIA NIH HHS R01 AG045611
6 · The paper itself

Abstract

Metabolic brain networks can provide insight into the network processes underlying progression from healthy aging to Alzheimer's disease. We explore the effect of two Alzheimer's disease risk factors, amyloid-β and ApoE ε4 genotype, on metabolic brain networks in cognitively normal older adults (N = 64, ages 69-89) compared to young adults (N = 17, ages 20-30) and patients with Alzheimer's disease (N = 22, ages 69-89). Subjects underwent MRI and PET imaging of metabolism (FDG) and amyloid-β (PIB). Normal older adults were divided into four subgroups based on amyloid-β and ApoE genotype. Metabolic brain networks were constructed cross-sectionally by computing pairwise correlations of metabolism across subjects within each group for 80 regions of interest. We found widespread elevated metabolic correlations and desegregation of metabolic brain networks in normal aging compared to youth and Alzheimer's disease, suggesting that normal aging leads to widespread loss of independent metabolic function across the brain. Amyloid-β and the combination of ApoE ε4 led to less extensive elevated metabolic correlations compared to other normal older adults, as well as a metabolic brain network more similar to youth and Alzheimer's disease. This could reflect early progression towards Alzheimer's disease in these individuals. Altered metabolic brain networks of older adults and those at the highest risk for progression to Alzheimer's disease open up novel lines of inquiry into the metabolic and network processes that underlie normal aging and Alzheimer's disease.

Indexed as

AdultAgedAged, 80 and overAge FactorsAgingAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsApolipoprotein E4BrainCorrelation of DataDisease ProgressionFemaleFluorodeoxyglucose F18HumansImage Processing, Computer-Assisted2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsApolipoprotein E4Fluorodeoxyglucose F18Thiazoles

Identifiers

PMID29527500
PMCPMC5842784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.